Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension
Background Resistant hypertension (RH) is linked to higher risks of cardiovascular events and there remains an unmet therapeutic need driven by pathophysiologic pathways unaddressed by guideline-recommended therapy. Whilst spironolactone is considered the preferred fourth-line therapy, its broad app...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Blood Pressure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/08037051.2024.2424824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|